Thermo Fisher Scientific Inc (TMO) - Total Assets

Latest as of September 2025: $103.02 Billion USD

Based on the latest financial reports, Thermo Fisher Scientific Inc (TMO) holds total assets worth $103.02 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore TMO cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Thermo Fisher Scientific Inc - Total Assets Trend (1985–2024)

This chart illustrates how Thermo Fisher Scientific Inc's total assets have evolved over time, based on quarterly financial data. See Thermo Fisher Scientific Inc (TMO) net assets for net asset value and shareholders' equity analysis.

Thermo Fisher Scientific Inc - Asset Composition Analysis

Current Asset Composition (December 2024)

Thermo Fisher Scientific Inc's total assets of $103.02 Billion consist of 22.8% current assets and 77.3% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $4.01 Billion 4.1%
Accounts Receivable $9.63 Billion 9.9%
Inventory $4.98 Billion 5.1%
Property, Plant & Equipment $10.79 Billion 11.1%
Intangible Assets $15.53 Billion 16.0%
Goodwill $45.85 Billion 47.1%

Asset Composition Trend (1985–2024)

This chart illustrates how Thermo Fisher Scientific Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Thermo Fisher Scientific Inc worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Thermo Fisher Scientific Inc's current assets represent 22.8% of total assets in 2024, a decrease from 59.3% in 1985.
  • Cash Position: Cash and equivalents constituted 4.1% of total assets in 2024, down from 13.5% in 1985.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 13.0% in 1985.
  • Asset Diversification: The largest asset category is goodwill at 47.1% of total assets.

Thermo Fisher Scientific Inc Competitors by Total Assets

Key competitors of Thermo Fisher Scientific Inc based on total assets are shown below.

Company Country Total Assets
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
China CN¥9.20 Billion
Cowealth Medical China Co.Ltd.
SHG:603122
China CN¥1.41 Billion
Prodia Widyahusada Tbk PT
JK:PRDA
Indonesia Rp2.57 Trillion
Sonic Healthcare Ltd
AU:SHL
Australia AU$17.03 Billion
Integral Diagnostics Ltd
AU:IDX
Australia AU$1.43 Billion
Australian Clinical Labs Ltd
AU:ACL
Australia AU$562.50 Million
Monash Ivf Group Ltd
AU:MVF
Australia AU$510.21 Million
Healius Ltd
AU:HLS
Australia AU$1.77 Billion

Thermo Fisher Scientific Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.50 1.63 2.13
Quick Ratio 1.11 1.26 1.74
Cash Ratio 0.00 0.32 0.00
Working Capital $7.41 Billion $9.18 Billion $11.65 Billion

Thermo Fisher Scientific Inc - Advanced Valuation Insights

This section examines the relationship between Thermo Fisher Scientific Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 4.32
Latest Market Cap to Assets Ratio 2.22
Asset Growth Rate (YoY) -1.4%
Total Assets $97.32 Billion
Market Capitalization $215.77 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values Thermo Fisher Scientific Inc's assets at a significant premium (2.22x), suggesting investors see substantial growth potential or unique competitive advantages.

Slight Asset Contraction: Thermo Fisher Scientific Inc's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Thermo Fisher Scientific Inc (1985–2024)

The table below shows the annual total assets of Thermo Fisher Scientific Inc from 1985 to 2024.

Year Total Assets Change
2024-12-31 $97.32 Billion -1.42%
2023-12-31 $98.73 Billion +1.62%
2022-12-31 $97.15 Billion +2.14%
2021-12-31 $95.12 Billion +37.76%
2020-12-31 $69.05 Billion +18.28%
2019-12-31 $58.38 Billion +3.82%
2018-12-31 $56.23 Billion -0.77%
2017-12-31 $56.67 Billion +23.44%
2016-12-31 $45.91 Billion +12.43%
2015-12-31 $40.83 Billion -4.71%
2014-12-31 $42.85 Billion +34.49%
2013-12-31 $31.86 Billion +16.10%
2012-12-31 $27.44 Billion +2.28%
2011-12-31 $26.83 Billion +25.47%
2010-12-31 $21.39 Billion -0.99%
2009-12-31 $21.60 Billion +2.42%
2008-12-31 $21.09 Billion -0.55%
2007-12-31 $21.21 Billion -0.26%
2006-12-31 $21.26 Billion +400.10%
2005-12-31 $4.25 Billion +18.87%
2004-12-31 $3.58 Billion +5.54%
2003-12-31 $3.39 Billion -7.08%
2002-12-31 $3.65 Billion -4.65%
2001-12-31 $3.83 Billion -21.34%
2000-12-31 $4.86 Billion -6.15%
1999-12-31 $5.18 Billion -18.16%
1998-12-31 $6.33 Billion +9.24%
1997-12-31 $5.80 Billion +12.73%
1996-12-31 $5.14 Billion +37.29%
1995-12-31 $3.74 Billion +24.01%
1994-12-31 $3.02 Billion +22.08%
1993-12-31 $2.47 Billion +36.04%
1992-12-31 $1.82 Billion +51.59%
1991-12-31 $1.20 Billion +33.54%
1990-12-31 $898.20 Million +44.03%
1989-12-31 $623.60 Million +27.24%
1988-12-31 $490.10 Million +15.02%
1987-12-31 $426.10 Million +37.94%
1986-12-31 $308.90 Million +39.33%
1985-12-31 $221.70 Million --

About Thermo Fisher Scientific Inc

NYSE:TMO USA Diagnostics & Research
Market Cap
$215.77 Billion
Market Cap Rank
#87 Global
#54 in USA
Share Price
$574.30
Change (1 day)
-0.43%
52-Week Range
$438.34 - $639.45
All Time High
$662.68
About

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines,… Read more